Highlights lecture EANM 2016: "Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine"

被引:17
作者
Aboagye, Eric O. [1 ]
Kraeber-Bodere, Francoise [2 ,3 ,4 ]
机构
[1] Imperial Coll London, Dept Surg & Canc, Canc Imaging Ctr, London, England
[2] Hotel Dieu Univ Hosp, Nucl Med, 1 Pl Alexis Ricordeau, F-44093 Nantes, France
[3] INSERM, U1232, CRCINA, Nantes, France
[4] ICO Canc Ctr, Nucl Med, St Herblain, France
关键词
Highlights lecture; EANM; Personalized medicine; Oncology; Cardiology; Neurosciences; PROGRESSION FREE SURVIVAL; PROSTATE-CANCER; BREAST-CANCER; RADIONUCLIDE THERAPY; RADIOLIGAND THERAPY; BIOCHEMICAL RELAPSE; RADIATION-EXPOSURE; GA-68-PSMA PET/CT; DIAGNOSTIC-VALUE; PROGNOSIS VALUE;
D O I
10.1007/s00259-017-3704-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The 2016 EANM Congress took place in Barcelona, Spain, from 15 to 19 October under the leadership of Prof. Wim Oyen, chair of the EANM Scientific Committee. With more than 6,000 participants, this congress was the most important European event in nuclear medicine, bringing together a multidisciplinary community involved in the different fields of nuclear medicine. There were over 600 oral and 1,200 poster or e-Poster presentations with an overwhelming focus on development and application of imaging for personalized care, which is timely for the community. Beyond FDG PET, major highlights included progress in the use of PSMA and SSTR receptor-targeted radiopharmaceuticals and associated theranostics in oncology. Innovations in radiopharmaceuticals for imaging pathologies of the brain and cardiovascular system, as well as infection and inflammation, were also highlighted. In the areas of physics and instrumentation, multimodality imaging and radiomics were highlighted as promising areas of research.
引用
收藏
页码:1559 / 1574
页数:16
相关论文
共 71 条
[1]  
Abgral R, 2016, EUR J NUCL MED MOL I, V43, pS61
[2]  
Antunovic L, 2016, EUR J NUCL MED MOL I, V43, pS75
[3]  
Bailly C, 2016, EUR J NUCL MED MOL I, V43, pS202
[4]   Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group [J].
Barrington, Sally F. ;
Mikhaeel, N. George ;
Kostakoglu, Lale ;
Meignan, Michel ;
Hutchings, Martin ;
Mueeller, Stefan P. ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Fisher, Richard I. ;
Trotman, Judith ;
Hoekstra, Otto S. ;
Hicks, Rodney J. ;
O'Doherty, Michael J. ;
Hustinx, Roland ;
Biggi, Alberto ;
Cheson, Bruce D. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3048-+
[5]   Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC [J].
Berliner, Christoph ;
Tienken, Milena ;
Frenzel, Thorsten ;
Kobayashi, Yuske ;
Helberg, Annabelle ;
Kirchner, Uve ;
Klutmann, Susanne ;
Beyersdorff, Dirk ;
Budaeus, Lars ;
Wester, Hans-Juergen ;
Mester, Janos ;
Bannas, Peter .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (04) :670-677
[6]   Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma [J].
Bossi, Paolo ;
Resteghini, Carlo ;
Paielli, Nicholas ;
Licitra, Lisa ;
Pilotti, Silvana ;
Perrone, Federica .
ONCOTARGET, 2016, 7 (45) :74362-74379
[7]  
Boughdad S, 2016, EUR J NUCL MED MOL I, V43, pS270
[8]  
Burley TA, 2016, EUR J NUCL MED MOL I, V43, pS231
[9]  
Ceci F, 2016, EUR J NUCL MED MOL I, V43, pS28
[10]  
Chen L, 2016, EUR J NUCL MED MOL I, V43, pS97